Ivabradine
- PDF / 169,381 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 93 Downloads / 173 Views
1 S
Ivabradine Various toxicities following off label use: 3 case reports
In a single centre, observational, retrospective, cohort study of 27 patients with postural orthostatic tachycardia syndrome treated between January 2015 to February 2019, three women aged 18 years* were described, who developed bradycardia, flushing, joint pain or fatigue following off-label treatment with ivabradine for postural orthostatic tachycardia syndrome [routes, duration of treatments to reactions onsets and outcomes not stated; not all dosages stated]. The women who had postural orthostatic tachycardia syndrome received off label treatment with ivabradine. However, two women developed joint pain and fatigue (n=1) and excessive flushing (n=1) and thus ivabradine was discontinued. While one women received ivabradine 5mg twice daily, but she developed severe bradycardia. As a result, her ivabradine dose was initially decreased from 5mg to 2.5mg twice daily and later discontinued. * Identifying patient details (three 18-year-old women) have been obtained through direct communication with the author. Towheed A, et al. Ivabradine in children with postural orthostatic tachycardia syndrome: A retrospective study. Cardiology in the Young 30: 975-979, No. 7, Jan 2020. 803519770 Available from: URL: http://doi.org/10.1017/S1047951120001341
0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Dec 2020 No. 1833
Data Loading...
